Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.
Authors
- P. Reguera Puertas
- O. Pablos
- Aida Orce
- Ana M. Peiró (ORCID: https://orcid.org/0000-0002-2385-3749)
- Roberto García‐Maroto (ORCID: https://orcid.org/0000-0001-6869-0069)
- I Chaves (ORCID: https://orcid.org/0009-0007-3793-3823)
- Manuel Rubio Angulo (ORCID: https://orcid.org/0000-0001-9194-1188)
- Miriam Maireles
- Francisco J. González-González (ORCID: https://orcid.org/0000-0003-3662-8695)
- Israel Pérez-Torres (ORCID: https://orcid.org/0000-0001-6510-2954)
- Gregorio Valero‐Cifuentes (ORCID: https://orcid.org/0000-0003-4331-6876)
- Paula González‐Rojo (ORCID: https://orcid.org/0000-0002-8560-1715)
- Carolina de la Calva (ORCID: https://orcid.org/0000-0001-8943-3483)
- Isidro Gracia
- Juan Luis Cebrián
- Antonio Valcárcel
- María del Carmen Sanz
- Pau Machado
- María Luisa Fontalva
- Luis Coll‐Mesa
Institutions
- Hospital de Sant Pau (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico San Carlos (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cnr2.70117
- Citations
- 2
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Universidad de Oviedo